Ulgastrin Uses

How long did you take this medication to work?
sponsored

What is Ulgastrin?

Ulgastrin is in a group of drugs called histamine-2 blockers. Ulgastrin works by reducing the amount of acid your stomach produces.

Ulgastrin is used to treat and prevent ulcers in the stomach and intestines. It also treats conditions in which the stomach produces too much acid, such as Zollinger-Ellison syndrome. Ulgastrin also treats gastroesophageal reflux disease (GERD) and other conditions in which acid backs up from the stomach into the esophagus, causing heartburn.

Ulgastrin may also be used for purposes not listed in this medication guide.

Ulgastrin indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Ulgastrin Tablets, USP are indicated in:

1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ulgastrin in uncomplicated duodenal ulcer for periods of more than 8 weeks.

2.Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year.

3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis).

4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated.

Studies available to date have not assessed the safety of Ulgastrin in uncomplicated, benign gastric ulcer for periods of more than 6 weeks.

5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year.

6.Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ulgastrin Tablets, USP 150 mg twice daily.

7.Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ulgastrin Tablets, USP 150 mg 4 times daily.

8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks.

Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.

How should I use Ulgastrin?

Use Ulgastrin tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Ulgastrin tablets.

Uses of Ulgastrin in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Ulgastrin is used to treat ulcers of the stomach and intestines and prevent them from coming back after they have healed. This medication is also used to treat certain stomach and throat (esophagus) problems (such as erosive esophagitis, gastroesophageal reflux disease-GERD, Zollinger-Ellison syndrome). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as cough that doesn't go away, stomach pain, heartburn, and difficulty swallowing. Ulgastrin belongs to a class of drugs known as H2 blockers.

This form of Ulgastrin is given by injection and is used for short-term treatment of these conditions when you cannot take this medication by mouth. Your doctor should switch you to taking this medication by mouth when possible.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

This medication may also be used to prevent ulcers caused by a certain class of drugs known as nonsteroidal anti-inflammatory drugs-NSAIDs (such as ibuprofen, naproxen). It may also be used to prevent stomach/intestinal bleeding.

How to use Ulgastrin injection

Read the Patient Information Leaflet if available from your pharmacist before you start using Ulgastrin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

This medication is given by injection into a vein or muscle as directed by your doctor. Premixed bags should only be given into a vein. The dosage and length of treatment are based on your medical condition and response to treatment. In children, the dosage may also be based on body weight.

If you are using this medication at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.

Tell your doctor if your condition does not improve or if it worsens.

Ulgastrin description

sponsored

An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as Ulgastrin and Ulgastrin. It is generally well tolerated by patients.

Ulgastrin dosage

Active Duodenal Ulcer:

The current recommended adult oral dosage of Ulgastrin for duodenal ulcer is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of Ulgastrin) twice daily. An alternative dosage of 300 mg or 20 mL of oral solution (4 teaspoonfuls of oral solution equivalent to 300 mg of Ulgastrin) once daily after the evening meal or at bedtime can be used for patients in whom dosing convenience is important. The advantages of one treatment regimen compared to the other in a particular patient population have yet to be demonstrated. Smaller doses have been shown to be equally effective in inhibiting gastric acid secretion in US studies, and several foreign trials have shown that 100 mg twice daily is as effective as the 150-mg dose.

Antacid should be given as needed for relief of pain.

Maintenance of Healing of Duodenal Ulcers:

The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of Ulgastrin) at bedtime.

Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome):

The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of Ulgastrin) twice daily. In some patients it may be necessary to administer Ulgastrin 150-mg doses more frequently. Dosages should be adjusted to individual patient needs, and should continue as long as clinically indicated. Dosages up to 6 g/day have been employed in patients with severe disease.

Benign Gastric Ulcer:

The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of Ulgastrin) twice daily.

Maintenance of Healing of Gastric Ulcers:

The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of Ulgastrin) at bedtime.

GERD:

The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of Ulgastrin) twice daily.

Erosive Esophagitis:

The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of Ulgastrin) 4 times daily.

Maintenance of Healing of Erosive Esophagitis:

The current recommended adult oral dosage is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of Ulgastrin) twice daily.

Pediatric Use:

The safety and effectiveness of Ulgastrin have been established in the age-group of 1 month to 16 years. There is insufficient information about the pharmacokinetics of Ulgastrin in neonatal patients (less than 1 month of age) to make dosing recommendations.

The following 3 subsections provide dosing information for each of the pediatric indications.

Treatment of Duodenal and Gastric Ulcers: The recommended oral dose for the treatment of active duodenal and gastric ulcers is 2 to 4 mg/kg twice daily to a maximum of 300 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.

Maintenance of Healing of Duodenal and Gastric Ulcers: The recommended oral dose for the maintenance of healing of duodenal and gastric ulcers is 2 to 4 mg/kg once daily to a maximum of 150 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.

Treatment of GERD and Erosive Esophagitis: Although limited data exist for these conditions in pediatric patients, published literature supports a dosage of 5 to 10 mg/kg/day, usually given as 2 divided doses.

Dosage Adjustment for Patients With Impaired Renal Function

On the basis of experience with a group of subjects with severely impaired renal function treated with Ulgastrin, the recommended dosage in patients with a creatinine clearance < 50 mL/min is 150 mg or 10 mL of oral solution (2 teaspoonfuls of oral solution equivalent to 150 mg of Ulgastrin) every 24 hours. Should the patient's condition require, the frequency of dosing may be increased to every 12 hours or even further with caution. Hemodialysis reduces the level of circulating Ulgastrin. Ideally, the dosing schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.

Elderly patients are more likely to have decreased renal function, therefore caution should be exercised in dose selection, and it may be useful to monitor renal function.

Ulgastrin interactions

See also:
What other drugs will affect Ulgastrin?

sponsored

In an application with antacids may decrease absorption of Ulgastrin.

In an application of Ulgastrin Dong-il with anticholinergics may be in breach of memory and attention in elderly patients.

Probably that histamine H2-blockers reduce receptor ulcerogenic action of NSAIDs on the gastric mucosa.

In an application with warfarin may decrease clearance of warfarin. There is one case of gipoprotrombinemiey and bleeding in patients receiving warfarin.

In an application with bismuth tripotassium dicitrate may increase unwanted absorption of bismuth, with glyburide - described the cases of hypoglycemia, with ketoconazole, itraconazole - decreased absorption of ketoconazole, itraconazole.

In an application with metoprolol may increase the plasma concentrations and increased AUC and T1 / 2 of metoprolol.

In an application with sucralfate in high doses (2 g) possible violation of the absorption of Ulgastrin.

In an application Ulgastrin Dong-il with procainamide may be decrease excretion of procainamide by the kidneys which leads to an increase in its concentration in blood plasma.

There is a data of increased absorption of triazolam in its simultaneous application, apparently due to changes in pH of gastric contents under the influence of Ulgastrin.

Probably that while the application with phenytoin may increase the concentration of phenytoin in plasma and increased risk of toxicity.

In an application with furosemide moderately expressed increasing the bioavailability of furosemide.

There is a described case of ventricular arrhythmias (bigeminy) with simultaneous application of quinidine, with cisapride - described a case of cardiotoxicity.

It can not be excluded some increase in cyclosporine concentration in blood plasma in its simultaneous application with Ulgastrin.

Ulgastrin side effects

See also:
What are the possible side effects of Ulgastrin?

The following have been reported as events in clinical trials or in the routine management of patients treated with Ulgastrin Tablets, USP. The relationship to therapy with Ulgastrin Tablets, USP has been unclear in many cases. Headache, sometimes severe, seems to be related to administration of Ulgastrin Tablets, USP.

Central Nervous System: Rarely, malaise, dizziness, somnolence, insomnia, and vertigo. Rare cases of reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients. Rare cases of reversible blurred vision suggestive of a change in accommodation have been reported. Rare reports of reversible involuntary motor disturbances have been received.

Cardiovascular: As with other H2-blockers, rare reports of arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats.

Gastrointestinal: Constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, and rare reports of pancreatitis.

Hepatic: There have been occasional reports of hepatocellular, cholestatic, or mixed hepatitis, with or without jaundice. In such circumstances, Ulgastrin should be immediately discontinued. These events are usually reversible, but in rare circumstances death has occurred. Rare cases of hepatic failure have also been reported. In normal volunteers, SGPT values were increased to at least twice the pretreatment levels in 6 of 12 subjects receiving 100 mg four times daily intravenously for 7 days, and in 4 of 24 subjects receiving 50 mg four times daily intravenously for 5 days.

Musculoskeletal: Rare reports of arthralgias and myalgias.

Hematologic: Blood count changes (leukopenia, granulocytopenia, and thrombocytopenia) have occurred in a few patients. These were usually reversible. Rare cases of agranulocytosis, pancytopenia, sometimes with marrow hypoplasia, and aplastic anemia and exceedingly rare cases of acquired immune hemolytic anemia have been reported.

Endocrine: Controlled studies in animals and man have shown no stimulation of any pituitary hormone by Ulgastrin Tablets, USP and no antiandrogenic activity, and Ulgastrin-induced gynecomastia and impotence in hypersecretory patients have resolved when Ulgastrin Tablets, USP have been substituted. However, occasional cases of gynecomastia, impotence, and loss of libido have been reported in male patients receiving Ulgastrin Tablets, USP, but the incidence did not differ from that in the general population.

Rare cases of breast symptoms and conditions, including galactorrhea and gynecomastia, have been reported in both males and females.

Integumentary: Rash, including rare cases of erythema multiforme. Rare cases of alopecia and vasculitis.

Respiratory: A large epidemiological study suggested an increased risk of developing pneumonia in current users of histamine-2-receptor antagonists (H2RAs) compared to patients who had stopped H2RA treatment, with an observed adjusted relative risk of 1.63 (95% CI, 1.07 to 2.48). However, a causal relationship between use of H2RAs and pneumonia has not been established.

Other: Rare cases of hypersensitiviy reactions (e.g., bronchospasm, fever, rash, eosinophilia), anaphylaxis, angioneurotic edema, acute interstitial nephritis, and small increases in serum creatinine.

Ulgastrin contraindications

See also:
What is the most important information I should know about Ulgastrin?

Hypersensitivity to Ulgastrin or any component of the formulation

OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food, vomiting with blood, or bloody or black stools, allergic to Ulgastrin or other acid reducers. Do not use with other acid reducers. Do not use 150 mg tablet with kidney disease without medical advice.

Documentation of allergenic cross-reactivity for histamine H antagonists is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Active ingredient matches for Ulgastrin:

Ranitidine in Mexico.

Al Na silicium/aluminium sodium silicate/anhydrous Na sulphate/anhydrous sodium sulfate/bismuth subnitrate/Extr glycyrrhizine siccum/Liquorice in Thailand.

Aluminium Sodium Silicate/Bismuth Subnitrate/Liquorice/Sodium Sulfate

Cimetidine in Brazil.

Aluminium sodium silicate/anhydrous sodium sulfate/bismuth subnitrate/Liquorice in Germany.


Unit description / dosage (Manufacturer)Price, USD
Ulgastrin 2 x 10's
Ulgastrin 42's

List of Ulgastrin substitutes (brand and generic names):

Ulfast 150mg Tablet (Sun Pharmaceutical Industries Ltd.)$ 0.01
Ulin 150 mg Tablet (Franklin Remedies)$ 0.01
Tablet, Film-Coated; Oral; Ranitidine Hydrochloride 150 mg (Krka)
Tablet, Film-Coated; Oral; Ranitidine Hydrochloride 300 mg (Krka)
Tablets, Film-Coated; Oral; Ranitidine Hydrochloride 150 mg (Krka)
Tablets, Film-Coated; Oral; Ranitidine Hydrochloride 300 mg (Krka)
Ulran 150 150 mg x 100's
Ulsafe 150 mg x 18's
Ulsafe 150 mg x 60's
Ulsafe 150 mg x 120's
Ulsamet 200 mg x 100's
Ulsamet 200 mg x 500's
Ulsamet 200 mg x 50 x 10's
Ulsamet 400 mg x 100's
Ulsamet 400 mg x 10 x 10's
Ulsamet 400 mg x 500's
Ulsamet 400 mg x 50 x 10's
Dragee; Oral; Ranitidine Hydrochloride 150 mg (Collins)
Dragee; Oral; Ranitidine Hydrochloride 300 mg (Collins)
Dragee; Oral; Ranitidine Hydrochloride 75 mg (Collins)
Ulsikur 200 mg x 10 x 10's (Hexpharm)$ 4.65
Ulsikur 400 mg x 10 x 5's (Hexpharm)$ 4.96
Ulsikur 200 mg x 5's (Hexpharm)$ 4.22
ULTAC Capsule/ Tablet / 300mg / 10 units (Cipla Limited)$ 0.58
ULTAC Capsule/ Tablet / 150mg / 10 units (Cipla Limited)$ 0.30
Ultac 150mg TAB / 10 (Cipla Limited)$ 0.08

References

  1. DailyMed. "POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. DailyMed. "CIMETIDINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  3. PubChem. "ranitidine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Ulgastrin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ulgastrin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


2 consumers reported price estimates

Was the price you paid to purchase the drug reasonable? Did you feel it was expensive?
The below mentioned numbers have been reported by ndrugs.com website users about whether the Ulgastrin drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
Users%
Not expensive2
100.0%


1 consumer reported time for results

To what extent do I have to use Ulgastrin before I begin to see changes in my health conditions?
As part of the reports released by ndrugs.com website users, it takes 2 weeks and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Ulgastrin. To get the time effectiveness of using Ulgastrin drug by other patients, please click here.
Users%
2 weeks1
100.0%


7 consumers reported age

Users%
> 604
57.1%
46-601
14.3%
16-291
14.3%
30-451
14.3%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 28 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved